A Multicenter, Phase 1, Open-Label, Dose Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 May 2018
At a glance
- Drugs ABBV 085 (Primary) ; Gemcitabine; Nivolumab; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 02 May 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2017 Planned End Date changed from 25 Jun 2020 to 28 Dec 2018.
- 15 Nov 2017 Planned primary completion date changed from 24 Dec 2018 to 29 Jun 2018.